CN Patent

CN103328474A — 细胞凋亡诱导剂的盐和晶形

Assigned to AbbVie Inc · Expires 2013-09-25 · 13y expired

What this patent protects

4-(4-{[2-(4-氯苯基)-4,4-二甲基环己-1-烯-1-基]甲基}哌嗪-1-基)-N-({3-硝基-4-[(四氢-2H-吡喃-4-基甲基)氨基]苯基}-磺酰基)-2-(1H-吡咯并[2,3-b]吡啶-5-基氧基)苯甲酰胺的盐和晶形是药物组合物的合适活性药物成分，该药物组合物可用于治疗特征在于一种或多种抗细胞凋亡Bcl-2家族蛋白过度表达的疾病，例如癌症。

USPTO Abstract

4-(4-{[2-(4-氯苯基)-4,4-二甲基环己-1-烯-1-基]甲基}哌嗪-1-基)-N-({3-硝基-4-[(四氢-2H-吡喃-4-基甲基)氨基]苯基}-磺酰基)-2-(1H-吡咯并[2,3-b]吡啶-5-基氧基)苯甲酰胺的盐和晶形是药物组合物的合适活性药物成分，该药物组合物可用于治疗特征在于一种或多种抗细胞凋亡Bcl-2家族蛋白过度表达的疾病，例如癌症。

Drugs covered by this patent

Patent Metadata

Patent number
CN103328474A
Jurisdiction
CN
Classification
—
Expires
2013-09-25
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.